Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ifrah

Showing results (71-80 of 169) with videos related to

Pageof 17
Sort By:
The Lancet. Oncology|July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsRobert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
American Journal of Hematology|November 21, 2018
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remissionXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2010
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemiaNicolas Chapuis, Jerome Tamburini, Alexa S Green, et al.
Blood|July 3, 2004
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiationPierre Feugier, Eric Labouyrie, Malika Djeridane, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Science Translational Medicine|May 27, 2021
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroupAurore Touzart, Anand Mayakonda, Charlotte Smith, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
Blood|January 24, 2012
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL studyPatrice Chevallier, Nelly Robillard, Aude Charbonnier, et al.
Cytometry. Part B, Clinical Cytometry|November 4, 2014
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter studyChantal Fossat, Mikael Roussel, Isabelle Arnoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyFrançoise Huguet, Thibaut Leguay, Emmanuel Raffoux, et al.
Pageof 17

Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
The Lancet. Oncology|July 11, 2014
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trialsRobert K Hills, Sylvie Castaigne, Frederick R Appelbaum, et al.
American Journal of Hematology|November 21, 2018
Hematopoietic stem cell transplantation for adult patients with isolated NPM1 mutated acute myeloid leukemia in first remissionXavier Poiré, Myriam Labopin, Emmanuelle Polge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2010
Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemiaNicolas Chapuis, Jerome Tamburini, Alexa S Green, et al.
Blood|July 3, 2004
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiationPierre Feugier, Eric Labouyrie, Malika Djeridane, et al.
Blood|April 26, 2018
Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemiaRaphael Itzykson, Nicolas Duployez, Annette Fasan, et al.
Science Translational Medicine|May 27, 2021
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroupAurore Touzart, Anand Mayakonda, Charlotte Smith, et al.
Blood|June 29, 2014
Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocationsJean-Baptiste Micol, Nicolas Duployez, Nicolas Boissel, et al.
Blood|January 24, 2012
Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL studyPatrice Chevallier, Nelly Robillard, Aude Charbonnier, et al.
Cytometry. Part B, Clinical Cytometry|November 4, 2014
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter studyChantal Fossat, Mikael Roussel, Isabelle Arnoux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2009
Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 studyFrançoise Huguet, Thibaut Leguay, Emmanuel Raffoux, et al.
Pageof 17